Inflammatory biomarkers and atherosclerosis

International Heart Journal

Volumn 57, Issue 2, 2016, Pages 134-139

  Soeki, Takeshi ^a   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Epicardial adipose tissue (EAT); Inflammation; MicroRNA (miRNA); Pentraxin 3 (PTX3)

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMMA INTERFERON INDUCIBLE PROTEIN 10; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD31 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MICRORNA; MICRORNA 147; MICRORNA 182; MICRORNA 208B; MICRORNA 499; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PADGEM PROTEIN; PENTRAXIN 3; REACTIVE OXYGEN METABOLITE; STROMELYSIN; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADIPOSE TISSUE; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CELL MIGRATION; COMPUTER ASSISTED TOMOGRAPHY; HEART FAILURE; INFLAMMATION; MACROPHAGE ACTIVATION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE CELL; VASCULITIS; BLOOD; HUMAN; METABOLISM;

ATHEROSCLEROSIS; BIOMARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION;

EID: 84961564419     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.15-346     Document Type: Review

References (49)

1. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332-9.
2. Williams KJ, Tabes I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-61. (Review)
3. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25. (Review)
4. Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.
5. Goldstein JA, Chandra HR, O’Neill WW. Relation of number of complex coronary lesions to serum C-reactive protein levels and major adverse cardiovascular events at one year. Am J Cardiol 2005; 96: 56-60.
6. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
7. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-22.
8. Weber C, Schober A, Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997-2008. (Review)
9. Niki T, Soeki T, Yamaguchi K, et al. Elevated concentration of interferon-inducible protein of 10 kD (IP-10) is associated with coronary atherosclerosis. Int Heart J 2015; 56: 269-72.
10. Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immunol 2000; 95: 135-44.
11. Matsuo Y, Kubo T, Okumoto Y, et al. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease. Eur Heart J Cardiovasc Imaging 2013; 14: 43-50.
12. Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm 2013; 2013: 152786. (Review)
13. Hayashida K, Kume N, Murase T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005; 112: 812-8.
14. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001; 14: 44S-54S. (Review)
15. Güray U, Erbay AR, Güray Y, et al. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. Int J Cardiol 2004; 96: 235-40.
16. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Increased soluble platelet/endothelial cell adhesion molecule-1 in the early stages of acute coronary syndromes. Int J Cardiol 2003; 90: 261-8.
17. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-20. (Review)
18. Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000; 83: 361-6. (Review)
19. Narula J, Finn AV, Demaria AN. Picking plaques that pop. J Am Coll Cardiol 2005; 45: 1970-3.
20. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17: 253-8. (Review)
21. Blankenberg S, Rupprecht HJ, Poirier O, et al; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
22. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000; 20: 1716-23. (Review)
23. Tavora FR, Ripple M, Li L, Burke AP. Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. BMC Cardiovasc Disord 2009; 9: 27.
24. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 50: 159-65.
25. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-604.
26. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2523-9.
27. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-44.
28. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-66. (Review)
29. Bonacina F, Baragetti A, Catapano AL, Norata GD. Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013; 2013: 725102. (Review)
30. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161-7.
31. Soeki T, Niki T, Kusunose K, et al. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol 2011; 58: 151-7.
32. Nebuloni M, Pasqualini F, Zerbi P, et al. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc Pathol 2011; 20: e27-35.
33. Latini R, Maggioni AP, Peri G, et al; Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-54.
34. Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011; 155: 425-33.
35. Latini R, Gullestad L, Masson S, et al; Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail 2012; 14: 992-9.
36. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117: 2369-76. (Review)
37. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-8.
38. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110: 483-95. (Review)
39. Takeishi Y. Biomarkers in heart failure. Int Heart J 2014; 55: 474-81. (Review)
40. De Rosa S, Fichtlscherer S, Lehmann R, Assmus B, Dimmeler S, Zeiher AM. Transcoronary concentration gradients of circulating microRNAs. Circulation 2011; 124: 1936-44.
41. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105: 1516-21.
42. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81.
43. Soeki T, Yamaguchi K, Niki T, et al. Plasma microRNA-100 is associated with coronary plaque vulnerability. Circ J 2015; 79: 413-8.
44. Kumada M, Kihara S, Sumitsuji S, et al; Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-9.
45. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-7.
46. Hirata Y, Tabata M, Kurobe H, et al. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol 2011; 58: 248-55.
47. Kim SH, Chung JH, Kwon BJ, Song SW, Choi WS. The associations of epicardial adipose tissue with coronary artery disease and coronary atherosclerosis. Int Heart J 2014; 55: 197-203.
48. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012; 379: 1205-13.
49. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214-24.